本帖最后由 StephenW 于 2011-7-31 22:47 编辑
一个新的临床试验:聚乙二醇干扰素+替诺福韦 - 组合,然后单泰诺福韦
http://clinicaltrials.gov/ct2/show/NCT01369212?term=Hiv&rcv_s=05/25/201...
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (HBRN)
This study is not yet open for participant recruitment.
Verified on July 2011 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First Received on June 6, 2011. Last Updated on July 20, 2011 History of Changes
Purpose This clinical trial compares the efficacy of peginterferon plus tenofovir for 24 weeks followed by monotherapy with tenofovir for a further 3.5 years to the efficacy of tenofovir alone given for 4 years in patients with chronic hepatitis B. The primary measure of outcome will be sustained HBsAg loss in serum one year after stopping all antiviral therapy (sustained off-treatment response).
Condition | Intervention | Hepatitis B
| Drug: Tenofovir
Drug: Combination of peginterferon alfa 2a and tenofovir
|
|